journal article·2020-08-12Open access

Surface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells

Xiyu Ke, Lillie Shelton, Yizong Hu, Yining Zhu, Emily Chow, Haoyu Tang, José Luis Santos, Hai-Quan Mao

ACS Applied Materials & Interfaces· Volume 12· Issue 32

Abstract

Nanoparticles designed as messenger RNA (mRNA) carriers to deliver gene medicine have shown great potential to change the way lung disease states are managed. Controlling their delivery to the lung and the transgene expression in a specific population of cells remains a challenge. Here, we developed a series of nanoparticles with polyethylene glycol (PEG) corona prepared by condensing mRNA with PEG-grafted-polyethyleneimine (PEI-g-PEG) with different PEG terminal functional groups and grafting ratios. PEGylated nanoparticles (PEG grafting ratio was 0.5%) with amino or amino acid terminal groups showed the highest transgene expression levels in the lung following systemic administration, and cell profiling analysis indicated that pulmonary immune cells contributed to the majority of expression. We also showed that these nanoparticles can be prepared by the flash nanocomplexation method, which is a scalable and reproducible process, yielding lyophilizable nanoparticles that were stable for at least 4 months at −20 °C. These results suggest that these surface-functionalized PEGylated nanoparticles may serve as desirable carriers to deliver mRNA to the lung for pulmonary immunomodulation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States

Department of Materials Science and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland 21218, United States

Department of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States

Department of Neurobiology and Behavior, Cornell University, Ithaca, New York 14850, United States

Biopharmaceuticals Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland 20878, United States

Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States

Funding

AstraZeneca · National Institute of Allergy and Infectious Diseases

References (48)

Show source-provided references
1. 10.1038/natrevmats.2017.5610.1038/natrevmats.2017.56 ↗
2. 10.1016/j.jconrel.2015.12.03210.1016/j.jconrel.2015.12.032 ↗
3. 10.1039/c4nr01346h10.1039/c4nr01346h ↗
4. 10.1002/jbm.a.3661410.1002/jbm.a.36614 ↗
5. 10.1002/adma.20160694410.1002/adma.201606944 ↗
6. 10.1021/acs.nanolett.5b0249710.1021/acs.nanolett.5b02497 ↗
7. 10.1002/anie.20180905610.1002/anie.201809056 ↗
8. 10.1002/adma.20190257510.1002/adma.201902575 ↗
9. 10.1002/anie.20160845010.1002/anie.201608450 ↗
10. 10.1016/j.jconrel.2010.09.00710.1016/j.jconrel.2010.09.007 ↗
11. 10.1371/journal.pone.005622010.1371/journal.pone.0056220 ↗
12. 10.1002/adhm.20180024910.1002/adhm.201800249 ↗
13. 10.1021/acs.nanolett.8b0291710.1021/acs.nanolett.8b02917 ↗
14. 10.1073/pnas.181127611510.1073/pnas.1811276115 ↗
15. 10.2174/138161282166615102715290710.2174/1381612821666151027152907 ↗
16. 10.1016/j.msec.2016.07.06610.1016/j.msec.2016.07.066 ↗
17. 10.1016/j.ymthe.2005.02.01010.1016/j.ymthe.2005.02.010 ↗
18. 10.1021/bm400462810.1021/bm4004628 ↗
19. 10.1016/j.jconrel.2012.07.01710.1016/j.jconrel.2012.07.017 ↗
20. 10.1021/acsbiomaterials.5b0055110.1021/acsbiomaterials.5b00551 ↗
21. 10.1016/j.actbio.2010.06.01610.1016/j.actbio.2010.06.016 ↗
22. 10.1016/j.nano.2019.04.00410.1016/j.nano.2019.04.004 ↗
23. 10.1002/smll.20160142510.1002/smll.201601425 ↗
24. 10.1016/j.biomaterials.2017.03.02810.1016/j.biomaterials.2017.03.028 ↗
25. 10.1021/acs.nanolett.8b0047810.1021/acs.nanolett.8b00478 ↗
26. 10.1016/j.ijpharm.2019.04.05310.1016/j.ijpharm.2019.04.053 ↗
27. 10.1016/j.jconrel.2019.03.01410.1016/j.jconrel.2019.03.014 ↗
28. 10.1021/acsnano.9b0333410.1021/acsnano.9b03334 ↗
29. 10.1038/1174310.1038/11743 ↗
30. 10.1126/sciadv.aay325510.1126/sciadv.aay3255 ↗
31. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
32. 10.1103/physreve.96.04240610.1103/physreve.96.042406 ↗
33. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
34. 10.1016/j.jconrel.2015.09.03110.1016/j.jconrel.2015.09.031 ↗
35. 10.1021/jacs.8b1002110.1021/jacs.8b10021 ↗
36. 10.1186/s12951-018-0401-y10.1186/s12951-018-0401-y ↗
37. 10.1038/s41434-018-0040-910.1038/s41434-018-0040-9 ↗
38. 10.1155/2015/68062010.1155/2015/680620 ↗
39. 10.1016/j.ymthe.2018.03.01010.1016/j.ymthe.2018.03.010 ↗
40. 10.1021/acsnano.8b0548210.1021/acsnano.8b05482 ↗
41. 10.1038/nature1074410.1038/nature10744 ↗
42. 10.1038/s41467-019-12906-y10.1038/s41467-019-12906-y ↗
43. 10.1002/adma.20150582210.1002/adma.201505822 ↗
44. 10.1159/00048705710.1159/000487057 ↗
45. 10.1038/ni.305210.1038/ni.3052 ↗
46. 10.1038/nm177010.1038/nm1770 ↗
47. 10.1038/ni.304810.1038/ni.3048 ↗
48. 10.1186/s40169-017-0175-010.1186/s40169-017-0175-0 ↗